Multidisciplinary COPD disease management program: Impact on clinical outcomes

Postgraduate Medicine

Volumn 128, Issue 2, 2016, Pages 239-249

  Morganroth, Melvin ^a   Pape, Ginger ^b   Rozenfeld, Yelena ^c   Heffner, John E ^d  

^a Oregon Clinic   (United States)

^b Providence Medical Group   (United States)

^c Providence Health and Services   (United States)

^d PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

COPD exacerbation; COPD guidelines; Disease management; Primary care

Indexed keywords

AGED; AMBULATORY CARE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; DECISION MAKING; DEMOGRAPHY; DISEASE EXACERBATION; EMERGENCY WARD; FEMALE; HEALTH CARE PLANNING; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERFORMANCE; PRIMARY MEDICAL CARE; QUASI EXPERIMENTAL STUDY; QUESTIONNAIRE; VACCINATION; CASE MANAGEMENT; CLINICAL DECISION SUPPORT SYSTEM; CONSTRUCTIVE FEEDBACK; FOLLOW UP; INFORMATION PROCESSING; INTERNET; MEDICAL EDUCATION; PATIENT CARE; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; CASE MANAGEMENT; CLUSTER ANALYSIS; DATA COLLECTION; DECISION SUPPORT SYSTEMS, CLINICAL; EDUCATION, MEDICAL, CONTINUING; FEMALE; FOLLOW-UP STUDIES; FORMATIVE FEEDBACK; GUIDELINE ADHERENCE; HUMANS; INTERNET; MALE; PATIENT CARE TEAM; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84964034630     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2016.1129259     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:938-943.
2. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139:165-173.
3. Makris D, Moschandreas J, Damianaki A, et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101:1305-1312.
4. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-1422.
5. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154:959-967.
6. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449-1455.
7. Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of chronic obstructive pulmonary disease: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.
8. Miravitlles M, Garcia-Polo C, Domenech A, et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013;191:523-530.
9. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347-365.
10. Grimshaw JM, Schunemann HJ, Burgers J, et al. Disseminating and implementing guidelines: article 13 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc. 2012;9:298-303.
11. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
12. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. Can Respir J. 2008;15(Suppl A):1A-8A.
13. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
14. Priest J, Buikema A, Engel-Nitz NM, et al. Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy. Popul Health Manag. 2012;15:101-112.
15. Mularski RA, Asch SM, Shrank WH, et al. The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes. Chest. 2006;130:1844-1850.
16. Sandhu SK, Chu J, Yurkovich M, et al. Variations in the management of acute exacerbations of chronic obstructive pulmonary disease. Can Respir J. 2013;20:175-179.
17. Kaminsky DA, Marcy TW, Bachand M, et al. Knowledge and use of office spirometry for the detection of chronic obstructive pulmonary disease by primary care physicians. Respir Care. 2005;50:1639-1648.
18. Walker PP, Mitchell P, Diamantea F, et al. Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J. 2006;28:945-952.
19. Feemster LC, Au DH. Penalizing hospitals for chronic obstructive pulmonary disease readmissions. Am J Respir Crit Care Med. 2014;189:634-639.
20. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775-1779.
21. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002;288:1909-1914.
22. Cramm JM, Nieboer AP. The relationship between selfmanagement abilities, quality of chronic care delivery, and wellbeing among patients with chronic obstructive pulmonary disease in The Netherlands. Int J Chron Obstruct Pulmon Dis. 2013;8:209-214.
23. Wootton R. Twenty years of telemedicine in chronic disease management-an evidence synthesis. J Telemed Telecare. 2012;18:211-220.
24. McKinstry B. The use of remote monitoring technologies in managing chronic obstructive pulmonary disease. QJM. 2013;106:883-885.
25. Kruis AL, Boland MR, Schoonvelde CH, et al. RECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. BMC Pulm Med. 2013;13:17.
26. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-555.
27. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117:398S-401S.
28. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-1138.
29. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29:527-534.
30. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008;26:4284-4289.
31. Walters JAE, Smith S, Poole P, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;(11). Art. No.: CD001390. doi:10.1002/14651858.CD001390.pub3.
32. Poole P, Chacko EE, Wood-Baker R, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(1). Art. No.: CD002733. doi:10.1002/14651858.CD002733.pub2
33. Strassmann R, Bausch B, Spaar A, et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009;34:634-640.
34. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134:43S-56S.
35. Omachi TA, Katz PP, Yelin EH, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med. 2009;122:778.e9-15.
36. Jennings JH, Digiovine B, Obeid D, et al. The association between depressive symptoms and acute exacerbations of COPD. Lung. 2009;187:128-135.
37. Cafarella PA, Effing TW, Usmani ZA, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology. 2012;17:627-638.
38. Farrero E, Escarrabill J, Prats E, et al. Impact of a hospitalbased home-care program on the management of COPD patients receiving long-term oxygen therapy. Chest. 2001;119:364-369.
39. Monteagudo M, Rodriguez-Blanco T, Llagostera M, et al. Effect of health professional education on outcomes of chronic obstructive pulmonary disease in primary care: a non-randomized clinical trial. Respirology. 2013;18:718-727.
40. Perencevich EN, Lautenbach E. Infection prevention and comparative effectiveness research. JAMA. 2011;305:1482-1483.
41. Torgerson DJ. Contamination in trials: is cluster randomisation the answer? BMJ. 2001;322:355-357.
42. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685-694.
43. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695-703.
44. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121:1058-1069.
45. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallelgroup, placebo-controlled study of low-dose, slowrelease theophylline in the treatment of COPD for 1 year. Respirology. 2006;11:603-610.
46. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187-194.
47. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-698.